{
    "organizations": [],
    "uuid": "dc13b75c15be8a82f63f8c554ca381f7b8896684",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-glaxosmithkline-submits-landmark-i/brief-glaxosmithkline-submits-landmark-impact-data-to-european-medicines-agency-to-support-expanded-label-for-trelegy-ellipta-idUSFWN1Q40G2",
    "ord_in_thread": 0,
    "title": "BRIEF-Glaxosmithkline Submits Landmark Impact Data To European Medicines Agency To Support Expanded Label For Trelegy Ellipta​",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 14 (Reuters) - Glaxosmithkline Plc:\n* ‍GSK SUBMITS LANDMARK IMPACT DATA TO EUROPEAN MEDICINES AGENCY TO SUPPORT EXPANDED LABEL FOR TRELEGY ELLIPTA​ Source text for Eikon: Further company coverage: (bangalore.newsroom@thomsonreuters.com)\n ",
    "published": "2018-02-14T17:41:00.000+02:00",
    "crawled": "2018-02-14T12:12:14.003+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "glaxosmithkline",
        "plc",
        "submits",
        "landmark",
        "impact",
        "data",
        "european",
        "medicine",
        "agency",
        "support",
        "expanded",
        "label",
        "trelegy",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}